
We have a robust and sustainable pipeline with 5 clinical stage assets (EMB-01, EMB-02 , EMB-06 , EMB-07 and EMB-09) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint regulators, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
Pipeline
Project
Targets
Indications
Rights
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
Partner
EMB-01
EGFR/cMET
Gastrointestinal cancers
Global
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in several GI indications in the U.S. and China.
EMB-06
BCMA/CD3
Multiple myeloma /autoimmune
Great China

EMB-06 is a recombinant humanized bispecific antibody targeted against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding to BCMA on cell surface, EMB-06 can recruit and activate CD3 expressing T lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor cells or the depletion B cells.
At 2025 ASH conference, the positive phase I results for EMB-06 in multiple myeloma was presented as an oral presentation.
In September 2024, based on its superior efficacy/safety profile, the right of ex-China of EMB-06 was licensed out to Vignette Bio, which is later acquired by Candid Therapeutics.
EMB-07
ROR1/CD3
Solid tumors /hematologic malignancies
Global
EMB-07 is a T cell engaging bispecific antibody targeting a novel tumor associated antigen ROR1. EMB-07 is designed based on EpimAb’s proprietary bispecific antibody platform. Upon binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3 expressing T lymphocytes, thereby promoting the cytotoxic effect of T lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile. EMB-07 is undergoing phase I trials.
EMB-09
PD-L1/OX40
Solid tumor
Global
EMB-09 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to block PD-1/PD-L1 inhibitory signaling, and conditionally activate T effector cells by stimulating OX40 through PD-L1 dependent cross linking. EMB-09 showed superior immune cell activation in comparison with the mAb combinations. Its unique OX40 binding epitope could improve the therapeutic window, and silenced Fc effector function can avoid T effector cell depletion.